Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for LifeVantage Corp’s latest consultant counts or product-line revenue without wading through dense text? Investors typically arrive here asking, “Where can I find LifeVantage’s quarterly earnings report 10-Q filing?” or “How do I track LifeVantage insider trading Form 4 transactions in real time?” This page bundles every SEC disclosure so you no longer jump between scattered EDGAR links.
Stock Titan’s AI reads each LifeVantage 8-K, 10-Q, and 10-K the moment it posts, then delivers plain-English summaries that flag shifts in independent-consultant enrollment, inventory risk and regulatory updates around nutrigenomic claims. Instead of skimming 200-plus pages, you’ll see the numbers that shape margins—net sales by product family, commission expense trends and emerging compliance issues—explained simply.
Use our quick-access tiles to drill into:
- Annual report 10-K simplified – pick out segment revenue, R&D on nutrigenomics and direct-sales compensation disclosures in minutes.
- Quarterly earnings report 10-Q – monitor consultant turnover, inventory levels and cash flow each quarter with AI-annotated highlights.
- Form 4 insider transactions – real-time alerts on LifeVantage executive stock moves so you can spot buying or selling trends fast.
- 8-K material events explained – leadership changes, product-safety notices or distributor policy updates distilled into key takeaways.
- Proxy statement executive compensation – understand how bonuses tie to enrolment growth and nutrigenomic product launches.
Whether you’re comparing quarters, dissecting compensation plans, or simply trying to “understand LifeVantage SEC documents with AI,” this hub keeps every filing current and comprehensible. Save hours, gain clarity, and turn regulatory disclosures into actionable insight.
The Capital Management Corporation reported beneficial ownership of 2,064,176 shares of LifeVantage Corporation common stock, representing 16.3% of the class. The filing shows the filer has sole voting power over 2,041,176 shares and sole dispositive power over 2,064,176 shares. The statement is filed on a Schedule 13G/A for the reporting period ending September 30, 2025 and includes a signed certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Contact and registration details identify Pamela C. Simms as Compliance Officer for The Capital Management Corporation, organized in Virginia.
LifeVantage Corporation is asking shareholders to vote on four routine proposals at its annual meeting, including election of seven directors and approval of an amendment to its 2017 Long-Term Incentive Plan that would add 400,000 shares to the reserve and extend the plan term to December 5, 2031. As of the Record Date, 12,691,009 shares were outstanding. The Board reports 71,500 option shares and 811,576 restricted stock/RSU awards outstanding under the plan and states 1,152,619 shares are available assuming maximum performance or 1,460,207 shares assuming target performance. The company reports a fair market stock price of $10.68 on the Record Date and estimates potential dilution would rise from 18.5% to 21.6% if the amendment is approved. The proxy describes executive pay structure changes (more PRSUs versus RSUs), recent dividend increases totaling $2.1M, and share repurchases of $3.1M (about 0.3M shares).
Darwin Lewis, a director of Lifevantage Corp (LFVN), reported an automatic purchase of common stock under a Rule 10b5-1 trading plan. On 09/16/2025 he acquired 450 shares at a price of $10.8499 per share, bringing his total beneficial ownership to 117,217 shares. The filing states the 10b5-1 plan was adopted on February 10, 2025. The Form 4 was signed on behalf of Mr. Lewis by a power of attorney on 09/18/2025. The report lists the transaction as a non-derivative acquisition and identifies Mr. Lewis as a director of the issuer.
Lifevantage Corp (LFVN) director Michael A. Beindorff reported insider sales on 09/09/2025. The Form 4 shows two open-market dispositions: 4,125 shares sold at $11.44 and 200 shares sold at $11.35. After these transactions, the filing reports 22,858 shares held directly by Mr. Beindorff and indirect holdings that include 126 shares held by spouse as custodian for minor children, 91,413 shares held by a trust, and 5,500 shares held indirectly by spouse. The filing notes the trust is the Michael A. Beindorff Trust dated 06/14/2000, of which the reporting person and his spouse are trustees.
LifeVantage Corporation disclosed that on
LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.
The Form 4 filed for LifeVantage Corp (LFVN) reports insider activity by CFO Carl Aure. On 08/31/2025 Mr. Aure had 14,792 and 18,886 Performance Restricted Stock Units (PRSUs) marked as acquired (codes M) that convert one-for-one into common stock when vesting criteria are met, and the filing notes those PRSUs were originally granted in 2023 and 2024. The report also reflects 718 shares purchased under the Employee Stock Purchase Plan, and a disposition of 16,610 shares sold at $13.10 per share. Following the transactions, the filing shows total beneficial ownership figures reported per line items.
Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.
Steven R. Fife, President and CEO and director of Lifevantage Corp (LFVN), reported insider transactions on 08/31/2025. Two tranches of previously granted performance restricted stock units converted into common stock: 90,718 shares (granted 08/24/2023) and 108,960 shares (granted 08/26/2024). Those PRSUs convert one-for-one into common shares and were reported as acquired at $0 under Rule 16 reporting codes. Separately, 98,177 shares were disposed of at a reported price of $13.10, leaving the reporting person with 761,001 and 859,178 total shares following the respective transactions as shown on the form.
Lifevantage Corp (LFVN) reporting person Alissa Neufeld recorded equity activity consisting of performance restricted stock units (PRSUs) and a disposition of common stock. The filing shows PRSUs granted in 2023 and 2024 that convert one-for-one into common stock, two grant-related transactions adding 14,498 and 18,886 shares (Transaction Code M) at $0 per share, and a sale (Transaction Code F) of 15,729 shares at $13.10 per share. After these transactions the reporting person beneficially owned 118,260 common shares.
The derivative section shows the PRSUs underlying 14,498 and 18,886 units, with post-transaction derivative beneficial ownership reported as 4,832 and 9,443 respectively. The filing states the PRSUs vest upon meeting pre-established time-based and financial performance criteria and convert into common stock on a one-for-one basis.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
